Cargando…
Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia
Early T-cell development is precisely controlled by E proteins, that indistinguishably include HEB/TCF12 and E2A/TCF3 transcription factors, together with NOTCH1 and pre-T cell receptor (TCR) signalling. Importantly, perturbations of early T-cell regulatory networks are implicated in leukemogenesis....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987207/ https://www.ncbi.nlm.nih.gov/pubmed/35401501 http://dx.doi.org/10.3389/fimmu.2022.867443 |
_version_ | 1784682689701347328 |
---|---|
author | Veiga, Diogo F. T. Tremblay, Mathieu Gerby, Bastien Herblot, Sabine Haman, André Gendron, Patrick Lemieux, Sébastien Zúñiga-Pflücker, Juan Carlos Hébert, Josée Cohen, Joseph Paul Hoang, Trang |
author_facet | Veiga, Diogo F. T. Tremblay, Mathieu Gerby, Bastien Herblot, Sabine Haman, André Gendron, Patrick Lemieux, Sébastien Zúñiga-Pflücker, Juan Carlos Hébert, Josée Cohen, Joseph Paul Hoang, Trang |
author_sort | Veiga, Diogo F. T. |
collection | PubMed |
description | Early T-cell development is precisely controlled by E proteins, that indistinguishably include HEB/TCF12 and E2A/TCF3 transcription factors, together with NOTCH1 and pre-T cell receptor (TCR) signalling. Importantly, perturbations of early T-cell regulatory networks are implicated in leukemogenesis. NOTCH1 gain of function mutations invariably lead to T-cell acute lymphoblastic leukemia (T-ALL), whereas inhibition of E proteins accelerates leukemogenesis. Thus, NOTCH1, pre-TCR, E2A and HEB functions are intertwined, but how these pathways contribute individually or synergistically to leukemogenesis remain to be documented. To directly address these questions, we leveraged Cd3e-deficient mice in which pre-TCR signaling and progression through β-selection is abrogated to dissect and decouple the roles of pre-TCR, NOTCH1, E2A and HEB in SCL/TAL1-induced T-ALL, via the use of Notch1 gain of function transgenic (Notch1IC(tg)) and Tcf12(+/-) or Tcf3(+/-) heterozygote mice. As a result, we now provide evidence that both HEB and E2A restrain cell proliferation at the β-selection checkpoint while the clonal expansion of SCL-LMO1-induced pre-leukemic stem cells in T-ALL is uniquely dependent on Tcf12 gene dosage. At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. Moreover, in SCL-LMO1-induced T-ALL, loss of one Tcf12 allele is sufficient to bypass pre-TCR signaling which is required for Notch1 gain of function mutations and for progression to T-ALL. In contrast, Tcf12 monoallelic deletion does not accelerate Notch1IC-induced T-ALL, indicating that Tcf12 and Notch1 operate in the same pathway. Finally, we identify a tumor suppressor gene set downstream of HEB, exhibiting significantly lower expression levels in pediatric T-ALL compared to B-ALL and brain cancer samples, the three most frequent pediatric cancers. In summary, our results indicate a tumor suppressor function of HEB/TCF12 in T-ALL to mitigate cell proliferation controlled by NOTCH1 in pre-leukemic stem cells and prevent NOTCH1-driven progression to T-ALL. |
format | Online Article Text |
id | pubmed-8987207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89872072022-04-08 Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia Veiga, Diogo F. T. Tremblay, Mathieu Gerby, Bastien Herblot, Sabine Haman, André Gendron, Patrick Lemieux, Sébastien Zúñiga-Pflücker, Juan Carlos Hébert, Josée Cohen, Joseph Paul Hoang, Trang Front Immunol Immunology Early T-cell development is precisely controlled by E proteins, that indistinguishably include HEB/TCF12 and E2A/TCF3 transcription factors, together with NOTCH1 and pre-T cell receptor (TCR) signalling. Importantly, perturbations of early T-cell regulatory networks are implicated in leukemogenesis. NOTCH1 gain of function mutations invariably lead to T-cell acute lymphoblastic leukemia (T-ALL), whereas inhibition of E proteins accelerates leukemogenesis. Thus, NOTCH1, pre-TCR, E2A and HEB functions are intertwined, but how these pathways contribute individually or synergistically to leukemogenesis remain to be documented. To directly address these questions, we leveraged Cd3e-deficient mice in which pre-TCR signaling and progression through β-selection is abrogated to dissect and decouple the roles of pre-TCR, NOTCH1, E2A and HEB in SCL/TAL1-induced T-ALL, via the use of Notch1 gain of function transgenic (Notch1IC(tg)) and Tcf12(+/-) or Tcf3(+/-) heterozygote mice. As a result, we now provide evidence that both HEB and E2A restrain cell proliferation at the β-selection checkpoint while the clonal expansion of SCL-LMO1-induced pre-leukemic stem cells in T-ALL is uniquely dependent on Tcf12 gene dosage. At the molecular level, HEB protein levels are decreased via proteasomal degradation at the leukemic stage, pointing to a reversible loss of function mechanism. Moreover, in SCL-LMO1-induced T-ALL, loss of one Tcf12 allele is sufficient to bypass pre-TCR signaling which is required for Notch1 gain of function mutations and for progression to T-ALL. In contrast, Tcf12 monoallelic deletion does not accelerate Notch1IC-induced T-ALL, indicating that Tcf12 and Notch1 operate in the same pathway. Finally, we identify a tumor suppressor gene set downstream of HEB, exhibiting significantly lower expression levels in pediatric T-ALL compared to B-ALL and brain cancer samples, the three most frequent pediatric cancers. In summary, our results indicate a tumor suppressor function of HEB/TCF12 in T-ALL to mitigate cell proliferation controlled by NOTCH1 in pre-leukemic stem cells and prevent NOTCH1-driven progression to T-ALL. Frontiers Media S.A. 2022-03-24 /pmc/articles/PMC8987207/ /pubmed/35401501 http://dx.doi.org/10.3389/fimmu.2022.867443 Text en Copyright © 2022 Veiga, Tremblay, Gerby, Herblot, Haman, Gendron, Lemieux, Zúñiga-Pflücker, Hébert, Cohen and Hoang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Veiga, Diogo F. T. Tremblay, Mathieu Gerby, Bastien Herblot, Sabine Haman, André Gendron, Patrick Lemieux, Sébastien Zúñiga-Pflücker, Juan Carlos Hébert, Josée Cohen, Joseph Paul Hoang, Trang Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia |
title | Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia |
title_full | Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia |
title_fullStr | Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia |
title_full_unstemmed | Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia |
title_short | Monoallelic Heb/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia |
title_sort | monoallelic heb/tcf12 deletion reduces the requirement for notch1 hyperactivation in t-cell acute lymphoblastic leukemia |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987207/ https://www.ncbi.nlm.nih.gov/pubmed/35401501 http://dx.doi.org/10.3389/fimmu.2022.867443 |
work_keys_str_mv | AT veigadiogoft monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia AT tremblaymathieu monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia AT gerbybastien monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia AT herblotsabine monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia AT hamanandre monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia AT gendronpatrick monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia AT lemieuxsebastien monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia AT zunigapfluckerjuancarlos monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia AT hebertjosee monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia AT cohenjosephpaul monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia AT hoangtrang monoallelichebtcf12deletionreducestherequirementfornotch1hyperactivationintcellacutelymphoblasticleukemia |